TABLE 2.
Basic characteristics of the murine models and experimental procedures from studies involving oral treatments of herbs and their active constituents.
| Age/Sex/Model species | Induction of AD-like skin lesions | Barrier disruption | Positive control drug | Investigation site | References |
|---|---|---|---|---|---|
| 4w/M/BALB/c mouse | DNCB | N/A | 1 mg/kg Dexamethasone | Dorsal skin | Lee JH et al. (2019) |
| 5w/M/BALB/c mouse | DNCB | N/A | 10 mg/kg Terfenadine | Dorsal skin | Ok et al. (2018) |
| 5w/M/BALB/c mouse | DNCB | N/A | 1 mg/kg Dexamethasone | Dorsal skin and ear | Yang et al. (2018) |
| 5w/M/BALB/c mouse | DNCB | N/A | 1 mg/kg Dexamethasone | Dorsal skin and ear | Zari and Zari, (2015) |
| 5w/M/BALB/c mouse | DNCB | N/A | N/A | Dorsal skin | Jung et al. (2014) |
| 5w/M/BALB/c mouse | DNCB | N/A | N/A | Dorsal skin | Park JH et al. (2019) |
| 5w/M/BALB/c mouse | DNFB | N/A | N/A | Dorsal skin | Kee et al. (2017) |
| 5w/M/BALB/c mouse | DNFB | N/A | N/A | Dorsal skin | Jeon et al. (2015) |
| 6w/M/BALB/c mouse | DNCB | N/A | N/A | Dorsal skin | Ku et al. (2017) |
| 6w/M/BALB/c mouse | DNCB | N/A | N/A | Dorsal skin | Kim SR et al. (2014) |
| 6–7w/M/BALB/c mouse | DfE | N/A | N/A | Ear | Makino et al. (2014) |
| 12w/M/BALB/c mouse | TMA | N/A | N/A | Ear | Sur et al. (2017) |
| M/BALB/c mouse | DNCB | N/A | 30 mg/kg Prednisolone | Dorsal skin and ear | Song-lin et al. (2014) |
| 4w/F/BALB/c mouse | DNCB and HDM (house dust mite) | Tape | Dexamethasone (dose not indicated) | Ear | Bae et al. (2016) |
| 5w/F/BALB/c mouse | Ovalbumin | Tape | 1 mg/kg Dexamethasone | Dorsal skin | Kong et al. (2015) |
| 6w/F/BALB/c mouse | DNCB and DfE | Tape | N/A | Ear | Choi et al. (2014b) |
| 6w/F/BALB/c mouse | DNCB and DfE | Tape | 1 mg/kg Dexamethasone | Ear | Jeong et al. (2018) |
| 6w/F/BALB/c mouse | Ovalbumin | Tape | 1.3 mg/kg Cetirizine | Dorsal skin | Chen et al. (2017) |
| 6–8w/F/BALB/c mouse | DNCB | N/A | 10 mg/kg Prednisolone | Dorsal skin | Meng et al. (2019) |
| 6–8w/F/BALB/c mouse | DNCB | N/A | 2.5 mg/kg Dexamethasone | Dorsal skin and ear | Chen et al. (2020) |
| 6–10w/BALB/c mouse | FITC | N/A | N/A | Ear | Tao et al. (2017) |
| 6–10w/BALB/c mouse | FITC | N/A | 0.67 mg/kg Dexamethasone | Ear | Wang et al. (2017) |
| 8w/F/BALB/c mouse | DNCB | N/A | N/A | Dorsal skin and ear | Han et al. (2016) |
| 8w/F/BALB/c mouse | Acetone and DNFB | N/A | 0.039 mg/kg Dexamethasone | Abdominal and dorsal skin | Han et al. (2018) |
| 8w/F/BALB/c mouse | TNCB and ovalbumin | N/A | 1.6 mg/kg Quercetin | Dorsal skin | Wu et al. (2014) |
| 8w/F/BALB/c mouse | DNFB | N/A | 10 nM Dexamethasone | Dorsal skin | Moon et al. (2019) |
| 8w/F/BALB/c mouse | Oxazolone | N/A | 2.5 mg/ml Dexamethasone | Dorsal skin and ear | Tsang et al. (2016) |
| F/BALB/c mouse | DNCB | N/A | 30 mg/kg Tacrolimus | Ear | Aslam et al. (2018) |
| 5w/BALB/c mouse | DNCB | N/A | N/A | Abdominal and dorsal skin | Zhanxue et al. (2018) |
| 6–8w/BALB/c mouse | FITC | N/A | 0.67 mg/kg Dexamethasone | Abdominal skin and ear | Xiao-Tong et al. (2019) |
| BALB/c mouse | FITC | N/A | 0.67 mg/kg Dexamethasone | Abdominal skin and ear | Zheng et al. (2019) |
| 1.3 mg/kg Loratadine | |||||
| 1.3 mg/kg Montelukast | |||||
| 3w/M/NC/Nga mouse | DfE | 5% SDS | N/A | Dorsal skin | Kim et al. (2020) |
| 3w/M/NC/Nga mouse | DNFB | Tape and 5% SDS | N/A | Dorsal skin | Cha et al. (2016) |
| 3w/M/NC/Nga mouse | DfE | Tape and 5% SDS | N/A | Dorsal skin | Cha HY et al. (2017) |
| 5w/M/NC/Nga mouse | DNCB | N/A | 3 mg/kg Prednisolone | Dorsal skin | Park et al. (2018) |
| 6w/M/NC/Nga mouse | DNCB | N/A | 3 mg/kg Dexamethasone | Dorsal skin | Park BK et al. (2014) |
| 6w/M/NC/Nga mouse | DNCB | N/A | 3 mg/kg Dexamethasone | Dorsal skin | Park et al. (2015) |
| 6w/M/NC/Nga mouse | DNFB | N/A | N/A | Dorsal skin | Lee et al. (2017) |
| 6w/M/NC/Nga mouse | DfE | 4% SDS | 5 mg/kg Dexamethasone | Dorsal skin | Kang et al. (2018) |
| 6–8w/M/NC/Nga mouse | DNCB | N/A | 3 mg/kg Dexamethasone | Dorsal skin, face and ear | Yan et al. (2019) |
| 8w/M/NC/Nga mouse | DfE | 4% SDS | 3 mg/kg Prednisolone | Dorsal skin and ear | Lim et al. (2014b) |
| 8w/M/NC/Nga mouse | DfE | 4% SDS | 3 mg/kg Prednisolone | Dorsal skin and ear | Lim et al. (2015) |
| M/NC/Nga mouse | DNFB | N/A | N/A | Abdominal and dorsal skin | Han et al. (2014a) |
| M/NC/Nga mouse | DNFB | N/A | 0.039 mg/kg Dexamethasone | Abdominal and dorsal skin | Han et al. (2014b) |
| 5w/F/NC/Nga mouse | DNCB | N/A | 5 mg/kg Dexamethasone | Dorsal skin | Cha KJ et al. (2017) |
| 4w/M/C57BL/6J mouse | DNFB | N/A | N/A | Dorsal skin | Park J et al. (2019) |
| 8w/IL-4/Luc/CNS-1 transgenic mouse | PA | N/A | N/A | Ear | Kwak et al. (2017) |
| 4w/M&F Lee/SD rat | DNCB | N/A | N/A | Dorsal skin and ear | Wan et al. (2016) |
N/A, Not applicable.